We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+6.39%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$5.88B
AUM Growth
-$490M
Cap. Flow
-$546M
Cap. Flow %
-9.3%
Top 10 Hldgs %
73.83%
Holding
50
New
3
Increased
19
Reduced
6
Closed
9

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$140M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$127M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$76.3M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$53.4M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$41.8M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$688M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$144M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$120M
4
TRIL
Trillium Therapeutics Inc.
TRIL
+$100M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$36.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1B 17.05%
9,295,000
+295,000
+3% +$32.2M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$744M 12.67%
5,075,000
+75,000
+2% +$11.6M
UTHR icon
3
United Therapeutics
UTHR
$26.1B
$656M 11.16%
3,035,000
+35,000
+1% +$6.87M
APLS
4
DELISTED
Apellis Pharmaceuticals
APLS
$405M 6.88%
8,555,555
+3,555,555
+71% +$140M
ARGX icon
5
argenx
ARGX
$55.2B
$338M 5.75%
965,000
+18,500
+2% +$5.63M
SRPT icon
6
Sarepta Therapeutics
SRPT
$1.64B
$281M 4.79%
3,125,000
+625,000
+25% +$53.4M
ASND icon
7
Ascendis Pharma A/S
ASND
$16.5B
$269M 4.58%
2,000,000
+20,000
+1% +$2.97M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$11.9B
$247M 4.21%
2,800,000
+925,000
+49% +$76.3M
FOLD
9
DELISTED
Amicus Therapeutics
FOLD
$214M 3.64%
18,500,000
+820,727
+5% +$9.15M
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$38.3B
$182M 3.1%
1,075,000
+225,000
+26% +$41.8M
IOVA icon
11
Iovance Biotherapeutics
IOVA
$2.04B
$166M 2.82%
8,675,000
+175,000
+2% +$3.85M
XENE icon
12
Xenon Pharmaceuticals
XENE
$6.1B
$156M 2.65%
4,985,000
+1,335,000
+37% +$39.9M
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$121M 2.06%
7,250,000
+150,000
+2% +$2.46M
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$12.6B
$121M 2.06%
1,425,000
– –
XBI icon
15
State Street SPDR S&P Biotech ETF
XBI
$10B
$118M 2%
+1,050,000
New +$127M
ARNA
16
DELISTED
Arena Pharmaceuticals Inc
ARNA
$115M 1.95%
1,235,000
-2,190,000
-64% -$144M
GLUE icon
17
Monte Rosa Therapeutics
GLUE
$1.82B
$67.6M 1.15%
3,311,434
– –
KURA icon
18
Kura Oncology
KURA
$793M
$56M 0.95%
4,000,000
– –
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$4.51B
$51.3M 0.87%
2,200,000
– –
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$1.7B
$47.6M 0.81%
2,175,000
+630,000
+41% +$11.6M
WHWK
21
Whitehawk Therapeutics
WHWK
$181M
$44.2M 0.75%
1,829,402
– –
MRSN
22
DELISTED
Mersana Therapeutics
MRSN
$42.3M 0.72%
272,000
– –
MNKD icon
23
MannKind Corp
MNKD
$1.19B
$38.5M 0.65%
8,800,000
– –
MRNS
24
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$38.4M 0.65%
3,235,000
– –
PRAX icon
25
Praxis Precision Medicines
PRAX
$8.11B
$35.1M 0.6%
118,667
+12,000
+11% +$3.52M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Avoro Capital Advisors held 50 positions worth $5.88B, down 7.7% from $6.37B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Avoro Capital Advisors withdrew a net $546M in Q4 2021, closing 9 positions and reducing 6 holdings. Its most notable exit was Acceleron Pharma, an estimated $688M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in State Street SPDR S&P Biotech ETF worth $118M.

  • Avoro Capital Advisors's largest Q4 2021 buy was State Street SPDR S&P Biotech ETF: 1,050,000 shares worth $118M.
  • Avoro Capital Advisors added most to Apellis Pharmaceuticals in Q4 2021, an estimated $140M increase.
  • Avoro Capital Advisors's biggest Q4 2021 reduction was Arena Pharmaceuticals Inc, cutting an estimated $144M.
  • Avoro Capital Advisors fully exited Acceleron Pharma in Q4 2021, selling an estimated $688M.
  • Avoro Capital Advisors's ten largest holdings make up 74% of its $5.88B portfolio in Q4 2021.
  • Avoro Capital Advisors opened 3 new positions and closed 9 in Q4 2021.
  • Avoro Capital Advisors's portfolio value fell 7.7% quarter-over-quarter to $5.88B.

Based on Avoro Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.